Ophthalmic Education:

Principles and Guidelines of a Curriculum for Education of the Ophthalmic Specialist: Appendix 1: Collaborative Ocular Melanoma Study (COMS) - Related Publications

On this page:

• Recommended Reading
  
  
• Additional Background Reading

Recommended Reading

Jones R, Gore E, Mieler W et al. Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects. Int J Radiat Oncol Biol Phys 2002; 52: 989-995

Sieving PA. Fifteen years of work: the COMS outcomes for medium-sized choroidal melanoma. Arch Ophthalmol 2001; 119: 1067-1068

Earle JD. Results from the Collaborative Ocular Melanoma Study (COMS) of enucleation versus preoperative radiation therapy in the management of large ocular melanomas. Int J Radiat Oncol Biol Phys 1999; 43: 1168-1169

Additional Background Reading

Marcus DM, Minkovitz JB, Wardwell SD, Albert DM. The value of nucleolar organizer regions in uveal melanoma. The Collaborative Ocular Melanoma Study Group. Am J Ophthalmol 1990; 110: 527-534

Markowitz JA, Hawkins BS, Diener-West M, Schachat AP. A review of mortality from choroidal melanoma. I. Quality of published reports, 1966 through 1988. Arch Ophthalmol 1992; 110: 239-244

Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992; 110: 245-250

Taylor KM. Integrating conflicting professional roles: physician participation in randomized clinical trials. Soc Sci Med 1992; 35: 217-224

Taylor KM. Physician participation in a randomized clinical trial for ocular melanoma. Ann Ophthalmol 1992; 24: 337-344

Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 1992; 36: 429-438

Soparker CN, O'Brien JM, Albert DM. Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. Invest Ophthalmol Vis Sci 1993; 34: 2203-2209

Hawkins BS, McBride R, Singer SW (eds). Data Management for Multicenter Studies: Methods and Guidelines. Controlled Clin Trials 16(2, suppl): 1-179, 1995. [This monograph includes several examples from COMS data management systems to illustrate current standards in multicenter clinical trials.]

Umlas J, Diener-West M, Robinson NL et al. Comparison of transillumination and histologic slide measurements of choroidal melanoma. Arch Ophthalmol 1997; 115: 474-477

Diener-West M, Connor PB, Newhouse MM, Hawkins BS. Feasibility of keying data from screen-displayed facsimile images in an ongoing trial: the collaborative ocular melanoma study. Control Clin Trials 1998; 19: 39-49

Ruiz RS, El-Harazi S, Albert DM, Bryar PJ. Cardiac metastasis of choroidal melanoma. Arch Ophthalmol 1999; 117: 1558-1559

Knutsen S, Hafslund R, Monge OR et al. Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy. Int J Radiat Oncol Biol Phys 2001; 51: 1159-1166

Grostern RJ, Slusker Shternfeld I, Bacus SS et al. Absence of type I estrogen receptors in choroidal melanoma: analysis of Collaborative Ocular Melanoma Study (COMS) eyes. Am J Ophthalmol 2001; 131: 788-791

Tabandeh H, Chaudhry NA, Murray TG et al. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol 2000; 129: 199-204

Albert DM. The ocular melanoma story. LIII Edward Jackson Memorial Lecture: Part II. Am J Ophthalmol 1997; 123: 729-741

Freire JE, De Potter P, Brady LW, Longton WA. Brachytherapy in primary ocular tumors. Semin Surg Oncol 1997; 13: 167-176

Reader S, Grigg J, Billson FA. Choroidal melanoma: a review of the experience of the Sydney Eye Hospital Professorial Unit 1979-1995. Aust N Z J Ophthalmol 1997; 25: 15-24

Char DH, Kroll S, Quivey JM, Castro J. Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy. Br J Ophthalmol 1996; 80: 117-124

Sanders DG, Mooy CM. Ocular findings in cerebro-ocular-myopathy syndrome (COMS). A possible role of growth factors? Int Ophthalmol 1993; 17: 223-228

Shields JA, Shields CL. Current management of posterior uveal melanoma. Mayo Clin Proc 1993; 68: 1196-1200

Next: Appendix 1: Additional Suggested Literature: Review Articles

Also see:

• Appendix 1: Oncology - Collaborative Ocular Melanoma Study (COMS)
  
  
• Table of Contents of the Principles and Guidelines of a Curriculum for Education of the Ophthalmic Specialist